Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...

Replimune (REPL) stock plummeted on Tuesday after the biotechnology company received a Complete Response Letter (CRL) from ...

J.P. Morgan analyst Anupam Rama maintained a Buy rating on AnaptysBio today and set a price target of $80.00. The company’s shares opened today at $28.15. Take advantage of TipRanks Premium at 50% off ...

Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...

Iova stock jumps 31% amid FDA setback for rival, short squeeze buzz, and rising momentum for Amtagvi melanoma therapy.

Vir Biotechnology has a strong cash position and is poised to generate definitive data in antivirals and oncology, making ...

Investing.com -- Replimune Group, Inc. (NASDAQ: REPL) stock plunged 77% after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) ...

European shares were mostly lower today. The eurozone's STOXX 600 slipped 0.48%, while Spain's IBEX 35 Index fell 0.35%.

Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 falling 0.11%, Hong Kong's Hang Seng gaining 0.54%, China's ...

Tesla Stock 2025 Price Target B ased on Wall Street analysts’ estimates, the median one-year price target for shares of TSLA is $299.52, which implies 8.13% potential upside from its current price.